Skip to main content

Find a trial

Find a trial

Trial status
Trial Phase
Trial type
334 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • DaNIS-2 A randomized, double-blind, phase III study, comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) pancreas phase 3 Closed
  • DANUBE A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer Bladder phase 3 Closed No prior exposure to immune-mediated therapy Thierry Gil
  • DCC-2618-03-002 A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib Stromal digestive tumors phase 3 Closed Progression or intolerance to imatinib Thierry Gil
  • DECRESCENDO De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Breast phase 2 Closed Andrea Gombos
  • DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2 An open-label, Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients Multiple phase 1 Closed any line Philippe Lewalle
  • DESIGN The DESIGN trial A randomised, Double-blind, placEbo-controlled Study to assess the effectIveness of pectoral nerves block (Pecs) after breast surGery on Piritramide coNsumption Breast phase 3 Closed Conservative or non-conservative breast surgery associated with axillary dissection
  • Destiny - Breast06 Phase III Study of Trastuzumab Deruxtecan versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive, Breast Cancer Patients whose Disease has Progressed On Endocrine Therapy in the Metastatic Setting Breast phase 3 Closed Andrea Gombos
  • DESTINY- Breast12 An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12) Breast phase 3/4 Open Andrea Gombos
  • DESTINY-PAN01 A Phase II, multicenter, open-label study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of unresectable and/or metastatic solid tumors harboring HER2 activating mutations regardless of tumor histology Multiple phase 2 Closed Philippe Aftimos
  • DS8201-A-U302 DS8201-A-U302 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer Breast phase 3 Closed HER2+. Metastatic/unresecable Andrea Gombos
  • DS8201-A-U303 A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2-low, HR-positive, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303) Breast phase 3 Closed HER2 low (+ or ++)/ER+ or ER-. Metastatic Andrea Gombos
  • DT-9081-CLI-001 A phase 1a, multicenter, open-label, dose-escalation study to determine a recommended clinical dose (RCD) of DT-9081, followed by an expansion study of DT-9081 at RCD in participants with advanced/metastatic solid tumours (DT-9081-CLI-001) Multiple phase 1 Open Nuria Kotecki
  • EFC15858/CARMEN-LC03 Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors Lung phase 3 Closed Mariana Brandao
  • ELDERLY Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicenter randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group Breast phase 2 Closed HER2+. Age Superior to 70 years old Lissandra Dal Lago